ASPEN- A Phase 3 Randomized Double-Blind Placebo-Controlled Study to Assess the Efficacy Safety and Tolerability of Brensocatib Administered Once Daily for 52 Weeks in Subjects With Non-Cystic Fibrosis Bronchiectasis
Brief description of study
Penn Medicine patients already participating in protocol INS1007 301 will be invited to participate in this study.
The Pharmacokinetic (PK) portion of this substudy is designed to evaluate the amount of brensocatib present in your blood at certain time periods before and after the study drug is administered, and the relationship of the amount (concentration) of brensocatib to how safe and effective it can be as a treatment for non-cystic fibrosis bronchiectasis (NCFBE).
The Pharmacodynamic (PD) portion of this substudy is designed to evaluate the amount of certain biomarkers (a biomarker is a substance in the body that indicates a process or condition is present) in your sputum, which in turn, can tell researchers whether brensocatib is having an effect on certain processes in your body, including an effect on the disease of NCFBE.
Eligibility of study
You may be eligible for this study if you meet the following criteria:
-
Conditions:
non-cystic fibrosis,bronchiectasis,non-cystic fibrosis bronchiectasis
-
Age: Between 18 Years - 85 Years
-
Gender: All
Updated on
09 Mar 2024.
Study ID: 848464
If you need assistance finding a non-cancer clinical research study or if you have any questions, please email psom-ocr@pobox.upenn.edu
For cancer trials contact EmergingMed: 1-855-216-0098 or PennCancerTrials@emergingmend.com
